Willow Biosciences Inc. WLLW Archives - Page 3 of 3

FridayAug 30, 2019 2:37 pm

QualityStocksNewsBreaks – Willow Biosciences Inc. (CSE: WLLW) Releases Q2 2019 Results and Provides Operational Update

Willow Biosciences (CSE: WLLW) today released its financial results for the three and six months ended June 30, 2019 and provided an operational update. Among highlights for the quarter, the company reported that it has: expanded its operations to include three facilities located in Calgary, Alberta, Mountain View, California and Burnaby, British Columbia; made key appointments to its management team and board of directors; entered an exclusive Joint Development Agreement (“JDA”) with Noramco; and completed a reverse takeover and raised gross proceeds of approximately $37.0 million. “Over the past few months, we have made impressive progress in advancing our business…

TuesdayJul 23, 2019 3:08 pm

QualityStocksNewsBreaks – Willow Biosciences Inc. (CSE: WLLW) Joint Development Agreement to Create Biosynthesis Platform for CBD Production, Distribution

Willow Biosciences (CSE: WLLW) recently entered a joint development agreement (“JDA”) with leading cannabinoid manufacturer Noramco Inc. to develop a yeast-based biosynthesis platform for the production and distribution of cannabidiol (“CBD”) (http://ibn.fm/8F330). An article further discussing the company reads, “The JDA is mutually exclusive and creates an enviable arrangement designed to take advantage of each company’s unique and compelling skill sets, the news release notes. The JDA requires each company to cover its own costs, retain its own intellectual property associated with its own scopes of work and share equally in the gross profits from sales of CBD produced under…

FridayJul 19, 2019 12:10 pm

QualityStocksNewsBreaks – Willow Biosciences Inc. (CSE: WLLW) Employs Proprietary Biosynthetic Processes to Develop Ultra-Pure CBD

Canada-based Willow Biosciences (CSE: WLLW) was recently featured in a video by InvestmentPitch Media detailing how the company utilizes its proprietary biosynthetic processes to deliver high yields of ultra-pure, low-cost cannabinoids. An article further discussing the company reads, “The video (http://ibn.fm/gRZL3) highlights a recent joint development agreement between Alberta, Canada-based Willow Biosciences and Delaware-headquartered Noramco that will build on Willow’s experience in developing manufacturing processes for active pharmaceutical ingredients (‘APIs’) that treat conditions such as cancer, pain and central nervous system disorders, as well as Noramco’s experience in producing high-quality, synthetic cannabinoid APIs for the pharmaceutical and health care industry.…

ThursdayJul 11, 2019 11:33 am

Willow Biosciences Inc. (CSE: WLLW) Developing Biosynthesis Platform for Production of Low-Cost, Pharmaceutical-Grade CBD

A joint development agreement signed with Noramco Inc., the world’s largest producer of chemically synthesized cannabinoids and pharmaceutical APIs, is expected to scale the development of Willow’s CBD biosynthesis program The collective market for CBD sales in the U.S. is expected to exceed $20 billion by 2024, while the cannabinoid-based pharmaceuticals market may reach $50 billion by 2029 Synthetic biology is expected to disrupt the cannabinoid industry supply chain, providing access to new and larger markets for CBD and related compounds Willow Biosciences Inc. (CSE: WLLW), a leading developer of biosynthetic production systems for high-value, plant-derived active pharmaceutical ingredients (APIs)…

WednesdayJul 10, 2019 2:15 pm

QualityStocksNewsBreaks – Why Willow Biosciences Inc. (CSE: WLLW) Is ‘One to Watch’

Alberta, Canada-based Willow Biosciences (CSE: WLLW) is a leading developer of biosynthetic production systems for high-value, plant-derived active pharmaceutical ingredients (“APIs”) and intermediates. A recent article discussing Willow Biosciences reads, “The company’s expertise in the esoteric field of biosynthesis and in delivering commercial fermentation pathways for the production of pharmaceutical-grade compounds grew from its origins in opiate research. Willow recently delivered a de novo biosynthesis pathway in yeast for thebaine, a key precursor API used as a feedstock in the manufacture of semi-synthetic opiates such as naloxone (used to reverse opioid overdose) and several common analgesics. Led by chief scientific…

TuesdayJul 09, 2019 11:32 am

Video Outlines Benefits of Willow Biosciences Inc.’s (CSE: WLLW) JDA to Develop CBD through Biosynthesis

Canada-based Willow Biosciences and U.S.-based Noramco are teaming to biosynthetically produce and market pharmaceutical-grade cannabidiol (CBD) The companies expect to deliver yeast-cultivated CBD as a low-cost, ultra-pure alternative to cannabis cultivation that avoids large-scale plant waste from greenhouse processes Yeast-grown pharmaceutical ingredients have long served as fodder for insulin and other important drugs; the growing interest in cannabis as a therapy is driving a booming new market The sea change in societal attitudes about cannabis, accompanied by the opening of governmental regulatory doors for its use (http://ibn.fm/KDlfq), has spawned a land rush by corporate interests set on staking out market territory…

WednesdayJun 26, 2019 10:08 am

Willow Biosciences Inc. (CSE: WLLW) is “One to Watch”

Exclusive joint development agreement with Noramco, the world’s largest producer of chemically synthesized cannabinoids and pharmaceutical APIs, to commercialize biosynthesized CBD Willow is fully funded with $37 million and expects to have more than $15 million on the balance sheet once the biosynthesized CBD isolate is ready to sell as a product Experienced research team with historical expertise in developing a biosynthesized API derived from the opium poppy, from the bench level to commercial scale-up Established laboratories in Calgary and Vancouver, Canada, and in San Francisco, all undergoing expansion U.S. CBD market potential in excess of $66 billion by 2025…

TuesdayJun 25, 2019 10:59 am

QualityStocksNewsBreaks – Willow Biosciences Inc. (CSE: WLLW) Enters Joint Development Agreement with Noramco Inc.

Willow Biosciences Inc. (CSE: WLLW), a leading developer of biosynthetic production systems for plant-derived active pharmaceutical ingredients (APIs) and intermediates, in early June announced its entry into an exclusive joint development agreement with Noramco Inc., a leading manufacturer of cannabinoids. Per the update, the two firms intend to collaboratively develop a yeast-based biosynthesis platform for the production and distribution of cannabidiol. Willow further notes that the work conducted through the agreement has the potential to open new and larger markets for CBD and related compounds. “Noramco is a world-class organization with a long history of developing APIs across numerous markets…

MondayJun 17, 2019 11:13 am

Willow Biosciences Inc. (CSE: WLLW) Enters Agreement with Noramco Inc. for Biosynthesis Platform

Willow has entered a joint development agreement with Noramco Inc. that includes a plan to develop a yeast-based biosynthesis platform to produce low-cost CBD for the pharmaceutical, food, beverage and personal care markets The agreement has the potential to open the door to new and larger markets for CBD and related compounds Terms of the agreement call for the parties to cover their own costs, retain their own intellectual property (IP) and share equally in gross profits Willow Biosciences Inc. (CSE: WLLW) has entered a joint development agreement (“JDA”) with Noramco Inc. to develop a biosynthesis platform for the production…

Site Search

Company Search

Tag: Willow Biosciences Inc. WLLW